nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—SLC6A3—Parkinson's disease	0.232	0.298	CbGaD
Nefazodone—HTR1A—Parkinson's disease	0.203	0.261	CbGaD
Nefazodone—HTR2A—Parkinson's disease	0.133	0.171	CbGaD
Nefazodone—CYP2D6—Parkinson's disease	0.122	0.157	CbGaD
Nefazodone—ABCB1—Parkinson's disease	0.0869	0.112	CbGaD
Nefazodone—SLC6A2—locus ceruleus—Parkinson's disease	0.00495	0.0569	CbGeAlD
Nefazodone—HTR2A—enteric nervous system—Parkinson's disease	0.00451	0.0518	CbGeAlD
Nefazodone—SLC6A2—sympathetic nervous system—Parkinson's disease	0.00391	0.0449	CbGeAlD
Nefazodone—HTR2A—myenteric nerve plexus—Parkinson's disease	0.00341	0.0392	CbGeAlD
Nefazodone—HTR2A—locus ceruleus—Parkinson's disease	0.00297	0.0342	CbGeAlD
Nefazodone—SLC6A3—telencephalic ventricle—Parkinson's disease	0.00291	0.0334	CbGeAlD
Nefazodone—HTR2C—telencephalic ventricle—Parkinson's disease	0.00281	0.0323	CbGeAlD
Nefazodone—SLC6A2—autonomic nervous system—Parkinson's disease	0.00263	0.0302	CbGeAlD
Nefazodone—HTR2A—cerebellar cortex—Parkinson's disease	0.00243	0.0279	CbGeAlD
Nefazodone—HTR1A—telencephalic ventricle—Parkinson's disease	0.00237	0.0272	CbGeAlD
Nefazodone—HTR2A—sympathetic nervous system—Parkinson's disease	0.00235	0.027	CbGeAlD
Nefazodone—SLC6A3—nerve—Parkinson's disease	0.00183	0.0211	CbGeAlD
Nefazodone—HTR2A—pons—Parkinson's disease	0.00171	0.0197	CbGeAlD
Nefazodone—HTR2A—autonomic nervous system—Parkinson's disease	0.00158	0.0182	CbGeAlD
Nefazodone—SLC6A2—nerve—Parkinson's disease	0.00148	0.017	CbGeAlD
Nefazodone—HTR2A—telencephalic ventricle—Parkinson's disease	0.00141	0.0162	CbGeAlD
Nefazodone—SLC6A3—hindbrain—Parkinson's disease	0.00137	0.0158	CbGeAlD
Nefazodone—ADRA2A—peripheral nervous system—Parkinson's disease	0.00134	0.0154	CbGeAlD
Nefazodone—SLC6A4—hindbrain—Parkinson's disease	0.00126	0.0145	CbGeAlD
Nefazodone—HTR2A—peripheral nervous system—Parkinson's disease	0.00114	0.0131	CbGeAlD
Nefazodone—HTR1A—hindbrain—Parkinson's disease	0.00112	0.0128	CbGeAlD
Nefazodone—ADRA1A—hindbrain—Parkinson's disease	0.00103	0.0118	CbGeAlD
Nefazodone—HTR2A—nerve—Parkinson's disease	0.000889	0.0102	CbGeAlD
Nefazodone—SLC6A3—brainstem—Parkinson's disease	0.000787	0.00904	CbGeAlD
Nefazodone—HTR2C—brainstem—Parkinson's disease	0.000761	0.00874	CbGeAlD
Nefazodone—SLC6A3—forebrain—Parkinson's disease	0.00076	0.00873	CbGeAlD
Nefazodone—HTR2C—forebrain—Parkinson's disease	0.000734	0.00844	CbGeAlD
Nefazodone—SLC6A4—brainstem—Parkinson's disease	0.000721	0.00829	CbGeAlD
Nefazodone—SLC6A4—forebrain—Parkinson's disease	0.000696	0.008	CbGeAlD
Nefazodone—HTR2A—hindbrain—Parkinson's disease	0.000666	0.00765	CbGeAlD
Nefazodone—HTR1A—brainstem—Parkinson's disease	0.00064	0.00736	CbGeAlD
Nefazodone—SLC6A2—brainstem—Parkinson's disease	0.000635	0.00729	CbGeAlD
Nefazodone—HTR1A—forebrain—Parkinson's disease	0.000618	0.0071	CbGeAlD
Nefazodone—SLC6A2—forebrain—Parkinson's disease	0.000613	0.00704	CbGeAlD
Nefazodone—CYP2D6—hindbrain—Parkinson's disease	0.000607	0.00697	CbGeAlD
Nefazodone—ADRA1A—brainstem—Parkinson's disease	0.00059	0.00678	CbGeAlD
Nefazodone—ADRA1B—head—Parkinson's disease	0.000581	0.00667	CbGeAlD
Nefazodone—ADRA1A—forebrain—Parkinson's disease	0.00057	0.00654	CbGeAlD
Nefazodone—ADRA1B—nervous system—Parkinson's disease	0.000551	0.00632	CbGeAlD
Nefazodone—HTR2C—medulla oblongata—Parkinson's disease	0.000531	0.00609	CbGeAlD
Nefazodone—ADRA1B—central nervous system—Parkinson's disease	0.00053	0.00609	CbGeAlD
Nefazodone—HTR1A—cardiovascular system—Parkinson's disease	0.000523	0.006	CbGeAlD
Nefazodone—SLC6A3—midbrain—Parkinson's disease	0.000502	0.00576	CbGeAlD
Nefazodone—SLC6A3—spinal cord—Parkinson's disease	0.000489	0.00562	CbGeAlD
Nefazodone—HTR2C—midbrain—Parkinson's disease	0.000485	0.00557	CbGeAlD
Nefazodone—ADRA1A—cardiovascular system—Parkinson's disease	0.000482	0.00553	CbGeAlD
Nefazodone—HTR2C—spinal cord—Parkinson's disease	0.000473	0.00543	CbGeAlD
Nefazodone—SLC6A4—midbrain—Parkinson's disease	0.00046	0.00528	CbGeAlD
Nefazodone—SLC6A4—spinal cord—Parkinson's disease	0.000448	0.00515	CbGeAlD
Nefazodone—SLC6A2—medulla oblongata—Parkinson's disease	0.000443	0.00509	CbGeAlD
Nefazodone—SLC6A3—head—Parkinson's disease	0.000435	0.005	CbGeAlD
Nefazodone—ADRA2A—forebrain—Parkinson's disease	0.000433	0.00498	CbGeAlD
Nefazodone—ADRA1B—brain—Parkinson's disease	0.000421	0.00483	CbGeAlD
Nefazodone—HTR2C—head—Parkinson's disease	0.00042	0.00483	CbGeAlD
Nefazodone—HTR2A—embryo—Parkinson's disease	0.000416	0.00478	CbGeAlD
Nefazodone—SLC6A3—nervous system—Parkinson's disease	0.000412	0.00474	CbGeAlD
Nefazodone—HTR1A—midbrain—Parkinson's disease	0.000408	0.00469	CbGeAlD
Nefazodone—HTR2C—nervous system—Parkinson's disease	0.000399	0.00458	CbGeAlD
Nefazodone—SLC6A4—head—Parkinson's disease	0.000399	0.00458	CbGeAlD
Nefazodone—HTR1A—spinal cord—Parkinson's disease	0.000398	0.00457	CbGeAlD
Nefazodone—SLC6A3—central nervous system—Parkinson's disease	0.000397	0.00456	CbGeAlD
Nefazodone—SLC6A3—cerebellum—Parkinson's disease	0.000388	0.00446	CbGeAlD
Nefazodone—HTR2C—central nervous system—Parkinson's disease	0.000384	0.00441	CbGeAlD
Nefazodone—HTR2A—brainstem—Parkinson's disease	0.000382	0.00438	CbGeAlD
Nefazodone—SLC6A4—nervous system—Parkinson's disease	0.000378	0.00434	CbGeAlD
Nefazodone—HTR2A—forebrain—Parkinson's disease	0.000368	0.00423	CbGeAlD
Nefazodone—Acetophenazine—DRD1—Parkinson's disease	0.000368	0.0472	CrCbGaD
Nefazodone—SLC6A4—central nervous system—Parkinson's disease	0.000364	0.00418	CbGeAlD
Nefazodone—HTR1A—head—Parkinson's disease	0.000354	0.00407	CbGeAlD
Nefazodone—SLC6A2—head—Parkinson's disease	0.000351	0.00403	CbGeAlD
Nefazodone—CYP2D6—brainstem—Parkinson's disease	0.000348	0.00399	CbGeAlD
Nefazodone—CYP2D6—forebrain—Parkinson's disease	0.000336	0.00385	CbGeAlD
Nefazodone—HTR1A—nervous system—Parkinson's disease	0.000336	0.00385	CbGeAlD
Nefazodone—SLC6A2—nervous system—Parkinson's disease	0.000333	0.00382	CbGeAlD
Nefazodone—ADRA1A—head—Parkinson's disease	0.000326	0.00375	CbGeAlD
Nefazodone—HTR1A—central nervous system—Parkinson's disease	0.000323	0.00371	CbGeAlD
Nefazodone—SLC6A2—central nervous system—Parkinson's disease	0.00032	0.00368	CbGeAlD
Nefazodone—HTR1A—cerebellum—Parkinson's disease	0.000316	0.00363	CbGeAlD
Nefazodone—SLC6A3—brain—Parkinson's disease	0.000315	0.00362	CbGeAlD
Nefazodone—ADRA2A—medulla oblongata—Parkinson's disease	0.000313	0.0036	CbGeAlD
Nefazodone—HTR2A—cardiovascular system—Parkinson's disease	0.000311	0.00358	CbGeAlD
Nefazodone—ADRA1A—nervous system—Parkinson's disease	0.000309	0.00355	CbGeAlD
Nefazodone—HTR2C—brain—Parkinson's disease	0.000305	0.0035	CbGeAlD
Nefazodone—ADRA1A—central nervous system—Parkinson's disease	0.000298	0.00342	CbGeAlD
Nefazodone—ADRA1A—cerebellum—Parkinson's disease	0.000291	0.00334	CbGeAlD
Nefazodone—SLC6A4—brain—Parkinson's disease	0.000289	0.00332	CbGeAlD
Nefazodone—ADRA2A—midbrain—Parkinson's disease	0.000286	0.00329	CbGeAlD
Nefazodone—Domperidone—DRD3—Parkinson's disease	0.000284	0.0364	CrCbGaD
Nefazodone—ADRA2A—spinal cord—Parkinson's disease	0.000279	0.00321	CbGeAlD
Nefazodone—ABCB1—embryo—Parkinson's disease	0.000273	0.00314	CbGeAlD
Nefazodone—HTR2A—medulla oblongata—Parkinson's disease	0.000266	0.00306	CbGeAlD
Nefazodone—Acetophenazine—DRD2—Parkinson's disease	0.00026	0.0332	CrCbGaD
Nefazodone—HTR1A—brain—Parkinson's disease	0.000256	0.00295	CbGeAlD
Nefazodone—SLC6A2—brain—Parkinson's disease	0.000254	0.00292	CbGeAlD
Nefazodone—ADRA2A—head—Parkinson's disease	0.000248	0.00285	CbGeAlD
Nefazodone—HTR2A—midbrain—Parkinson's disease	0.000243	0.00279	CbGeAlD
Nefazodone—ABCB1—forebrain—Parkinson's disease	0.000241	0.00277	CbGeAlD
Nefazodone—HTR2A—spinal cord—Parkinson's disease	0.000237	0.00273	CbGeAlD
Nefazodone—ADRA1A—brain—Parkinson's disease	0.000236	0.00272	CbGeAlD
Nefazodone—ADRA2A—nervous system—Parkinson's disease	0.000235	0.0027	CbGeAlD
Nefazodone—Aripiprazole—HTR7—Parkinson's disease	0.000233	0.0299	CrCbGaD
Nefazodone—Zuclopenthixol—DRD1—Parkinson's disease	0.000233	0.0299	CrCbGaD
Nefazodone—ADRA2A—central nervous system—Parkinson's disease	0.000226	0.0026	CbGeAlD
Nefazodone—ADRA2A—cerebellum—Parkinson's disease	0.000221	0.00254	CbGeAlD
Nefazodone—Aripiprazole—DRD3—Parkinson's disease	0.000219	0.0281	CrCbGaD
Nefazodone—Hydroxyzine—CYP2D6—Parkinson's disease	0.000216	0.0276	CrCbGaD
Nefazodone—Aripiprazole—DRD1—Parkinson's disease	0.000215	0.0276	CrCbGaD
Nefazodone—HTR2A—head—Parkinson's disease	0.000211	0.00242	CbGeAlD
Nefazodone—Thioproperazine—DRD1—Parkinson's disease	0.000204	0.0262	CrCbGaD
Nefazodone—ABCB1—cardiovascular system—Parkinson's disease	0.000204	0.00234	CbGeAlD
Nefazodone—HTR2A—nervous system—Parkinson's disease	0.0002	0.0023	CbGeAlD
Nefazodone—Domperidone—DRD2—Parkinson's disease	0.000197	0.0252	CrCbGaD
Nefazodone—Prochlorperazine—DRD3—Parkinson's disease	0.000196	0.0251	CrCbGaD
Nefazodone—HTR2A—central nervous system—Parkinson's disease	0.000193	0.00221	CbGeAlD
Nefazodone—CYP2D6—head—Parkinson's disease	0.000192	0.00221	CbGeAlD
Nefazodone—HTR2A—cerebellum—Parkinson's disease	0.000188	0.00216	CbGeAlD
Nefazodone—CYP3A4—nervous system—Parkinson's disease	0.000185	0.00213	CbGeAlD
Nefazodone—CYP2D6—nervous system—Parkinson's disease	0.000182	0.00209	CbGeAlD
Nefazodone—ADRA2A—brain—Parkinson's disease	0.00018	0.00206	CbGeAlD
Nefazodone—Aripiprazole—HTR1A—Parkinson's disease	0.000179	0.0229	CrCbGaD
Nefazodone—CYP3A4—central nervous system—Parkinson's disease	0.000178	0.00205	CbGeAlD
Nefazodone—Trazodone—HTR1A—Parkinson's disease	0.000178	0.0228	CrCbGaD
Nefazodone—Fluphenazine—DRD3—Parkinson's disease	0.000177	0.0227	CrCbGaD
Nefazodone—CYP2D6—central nervous system—Parkinson's disease	0.000175	0.00201	CbGeAlD
Nefazodone—ABCB1—medulla oblongata—Parkinson's disease	0.000174	0.002	CbGeAlD
Nefazodone—Fluphenazine—DRD1—Parkinson's disease	0.000174	0.0222	CrCbGaD
Nefazodone—CYP2D6—cerebellum—Parkinson's disease	0.000171	0.00197	CbGeAlD
Nefazodone—Thioproperazine—HTR1A—Parkinson's disease	0.00017	0.0217	CrCbGaD
Nefazodone—Zuclopenthixol—DRD2—Parkinson's disease	0.000164	0.021	CrCbGaD
Nefazodone—ABCB1—midbrain—Parkinson's disease	0.000159	0.00183	CbGeAlD
Nefazodone—ABCB1—spinal cord—Parkinson's disease	0.000156	0.00179	CbGeAlD
Nefazodone—HTR2A—brain—Parkinson's disease	0.000153	0.00176	CbGeAlD
Nefazodone—Aripiprazole—DRD2—Parkinson's disease	0.000152	0.0195	CrCbGaD
Nefazodone—Perphenazine—HTR7—Parkinson's disease	0.000149	0.0191	CrCbGaD
Nefazodone—Quetiapine—HTR7—Parkinson's disease	0.000146	0.0187	CrCbGaD
Nefazodone—Fluphenazine—HTR1A—Parkinson's disease	0.000144	0.0185	CrCbGaD
Nefazodone—Thioproperazine—DRD2—Parkinson's disease	0.000144	0.0184	CrCbGaD
Nefazodone—CYP2D6—brain—Parkinson's disease	0.000139	0.0016	CbGeAlD
Nefazodone—Domperidone—CYP2D6—Parkinson's disease	0.000139	0.0178	CrCbGaD
Nefazodone—ABCB1—head—Parkinson's disease	0.000138	0.00159	CbGeAlD
Nefazodone—Perphenazine—DRD1—Parkinson's disease	0.000137	0.0176	CrCbGaD
Nefazodone—Quetiapine—DRD3—Parkinson's disease	0.000137	0.0176	CrCbGaD
Nefazodone—Prochlorperazine—DRD2—Parkinson's disease	0.000135	0.0173	CrCbGaD
Nefazodone—Quetiapine—DRD1—Parkinson's disease	0.000135	0.0172	CrCbGaD
Nefazodone—ABCB1—nervous system—Parkinson's disease	0.000131	0.00151	CbGeAlD
Nefazodone—Zuclopenthixol—HTR2A—Parkinson's disease	0.000127	0.0163	CrCbGaD
Nefazodone—ABCB1—central nervous system—Parkinson's disease	0.000126	0.00145	CbGeAlD
Nefazodone—ABCB1—cerebellum—Parkinson's disease	0.000123	0.00142	CbGeAlD
Nefazodone—Fluphenazine—DRD2—Parkinson's disease	0.000122	0.0157	CrCbGaD
Nefazodone—Fluphenazine—CYP2E1—Parkinson's disease	0.000118	0.0151	CrCbGaD
Nefazodone—Aripiprazole—HTR2A—Parkinson's disease	0.000117	0.015	CrCbGaD
Nefazodone—Trazodone—HTR2A—Parkinson's disease	0.000117	0.015	CrCbGaD
Nefazodone—Zuclopenthixol—CYP2D6—Parkinson's disease	0.000116	0.0149	CrCbGaD
Nefazodone—Trifluoperazine—HTR1A—Parkinson's disease	0.000115	0.0148	CrCbGaD
Nefazodone—Perphenazine—HTR1A—Parkinson's disease	0.000114	0.0146	CrCbGaD
Nefazodone—Quetiapine—HTR1A—Parkinson's disease	0.000112	0.0143	CrCbGaD
Nefazodone—Thioproperazine—HTR2A—Parkinson's disease	0.000111	0.0143	CrCbGaD
Nefazodone—Aripiprazole—CYP2D6—Parkinson's disease	0.000107	0.0137	CrCbGaD
Nefazodone—Trazodone—CYP2D6—Parkinson's disease	0.000107	0.0137	CrCbGaD
Nefazodone—ABCB1—brain—Parkinson's disease	0.0001	0.00115	CbGeAlD
Nefazodone—Domperidone—ABCB1—Parkinson's disease	9.93e-05	0.0127	CrCbGaD
Nefazodone—Trifluoperazine—DRD2—Parkinson's disease	9.79e-05	0.0125	CrCbGaD
Nefazodone—Perphenazine—DRD2—Parkinson's disease	9.68e-05	0.0124	CrCbGaD
Nefazodone—Prochlorperazine—CYP2D6—Parkinson's disease	9.57e-05	0.0123	CrCbGaD
Nefazodone—Quetiapine—DRD2—Parkinson's disease	9.49e-05	0.0122	CrCbGaD
Nefazodone—Fluphenazine—HTR2A—Parkinson's disease	9.46e-05	0.0121	CrCbGaD
Nefazodone—Fluphenazine—CYP2D6—Parkinson's disease	8.65e-05	0.0111	CrCbGaD
Nefazodone—Aripiprazole—ABCB1—Parkinson's disease	7.66e-05	0.00982	CrCbGaD
Nefazodone—Trazodone—ABCB1—Parkinson's disease	7.63e-05	0.00977	CrCbGaD
Nefazodone—Trifluoperazine—HTR2A—Parkinson's disease	7.56e-05	0.00969	CrCbGaD
Nefazodone—Perphenazine—HTR2A—Parkinson's disease	7.48e-05	0.00958	CrCbGaD
Nefazodone—Quetiapine—HTR2A—Parkinson's disease	7.33e-05	0.0094	CrCbGaD
Nefazodone—Perphenazine—CYP2D6—Parkinson's disease	6.84e-05	0.00876	CrCbGaD
Nefazodone—Quetiapine—CYP2D6—Parkinson's disease	6.71e-05	0.00859	CrCbGaD
Nefazodone—Fluphenazine—ABCB1—Parkinson's disease	6.18e-05	0.00791	CrCbGaD
Nefazodone—Trifluoperazine—ABCB1—Parkinson's disease	4.94e-05	0.00633	CrCbGaD
Nefazodone—Quetiapine—ABCB1—Parkinson's disease	4.79e-05	0.00614	CrCbGaD
Nefazodone—HTR2C—Signaling Pathways—INSR—Parkinson's disease	1.42e-05	0.00011	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—CYP2E1—Parkinson's disease	1.41e-05	0.00011	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—HTR2A—Parkinson's disease	1.41e-05	0.00011	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—TALDO1—Parkinson's disease	1.4e-05	0.000109	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—OMD—Parkinson's disease	1.4e-05	0.000109	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—NQO1—Parkinson's disease	1.4e-05	0.000109	CbGpPWpGaD
Nefazodone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Parkinson's disease	1.39e-05	0.000108	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—FGF20—Parkinson's disease	1.38e-05	0.000107	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—TH—Parkinson's disease	1.38e-05	0.000107	CbGpPWpGaD
Nefazodone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Parkinson's disease	1.37e-05	0.000106	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—INSR—Parkinson's disease	1.36e-05	0.000106	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—FGF20—Parkinson's disease	1.35e-05	0.000105	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—FGB—Parkinson's disease	1.35e-05	0.000105	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—DDC—Parkinson's disease	1.35e-05	0.000105	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—HTR2A—Parkinson's disease	1.35e-05	0.000105	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—FGB—Parkinson's disease	1.34e-05	0.000104	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—HTR2A—Parkinson's disease	1.34e-05	0.000104	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	1.34e-05	0.000104	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ADORA2A—Parkinson's disease	1.34e-05	0.000104	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HTR1A—Parkinson's disease	1.34e-05	0.000104	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—EDN1—Parkinson's disease	1.33e-05	0.000104	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NDUFB11—Parkinson's disease	1.33e-05	0.000103	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—EDN1—Parkinson's disease	1.33e-05	0.000103	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—CYCS—Parkinson's disease	1.32e-05	0.000103	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TAC1—Parkinson's disease	1.32e-05	0.000103	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TAC1—Parkinson's disease	1.32e-05	0.000102	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ADORA2A—Parkinson's disease	1.31e-05	0.000102	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—EDN1—Parkinson's disease	1.3e-05	0.000101	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—DRD1—Parkinson's disease	1.3e-05	0.000101	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—DRD1—Parkinson's disease	1.29e-05	0.0001	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—FGB—Parkinson's disease	1.29e-05	9.99e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—HTR2A—Parkinson's disease	1.28e-05	9.97e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HTR1A—Parkinson's disease	1.28e-05	9.94e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GSTA4—Parkinson's disease	1.27e-05	9.89e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—DDC—Parkinson's disease	1.27e-05	9.87e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GCH1—Parkinson's disease	1.27e-05	9.86e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TAC1—Parkinson's disease	1.26e-05	9.79e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—DRD3—Parkinson's disease	1.26e-05	9.76e-05	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—HTR2A—Parkinson's disease	1.25e-05	9.75e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—FGF20—Parkinson's disease	1.25e-05	9.75e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—DRD3—Parkinson's disease	1.25e-05	9.71e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—DRD1—Parkinson's disease	1.23e-05	9.6e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—INSR—Parkinson's disease	1.23e-05	9.59e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CYP2D6—Parkinson's disease	1.22e-05	9.48e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ADORA2A—Parkinson's disease	1.22e-05	9.45e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—EDN1—Parkinson's disease	1.21e-05	9.41e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—INSR—Parkinson's disease	1.21e-05	9.39e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSTA4—Parkinson's disease	1.2e-05	9.32e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CTGF—Parkinson's disease	1.2e-05	9.3e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—DRD3—Parkinson's disease	1.2e-05	9.3e-05	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Parkinson's disease	1.2e-05	9.29e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ADRBK1—Parkinson's disease	1.17e-05	9.12e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—COMT—Parkinson's disease	1.17e-05	9.1e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ADRBK1—Parkinson's disease	1.17e-05	9.07e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—FGB—Parkinson's disease	1.17e-05	9.06e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—GSTP1—Parkinson's disease	1.17e-05	9.06e-05	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—HTR2A—Parkinson's disease	1.17e-05	9.06e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—MAOA—Parkinson's disease	1.16e-05	9.04e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—HTR1A—Parkinson's disease	1.16e-05	9.02e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—HMOX1—Parkinson's disease	1.15e-05	8.94e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PLA2G6—Parkinson's disease	1.15e-05	8.91e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TAC1—Parkinson's disease	1.14e-05	8.88e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—FGB—Parkinson's disease	1.14e-05	8.88e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—HTR2A—Parkinson's disease	1.14e-05	8.86e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HTR1A—Parkinson's disease	1.14e-05	8.83e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—HTR7—Parkinson's disease	1.14e-05	8.83e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—DRD2—Parkinson's disease	1.14e-05	8.83e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—MAOB—Parkinson's disease	1.13e-05	8.82e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GBA—Parkinson's disease	1.13e-05	8.79e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—FBP1—Parkinson's disease	1.13e-05	8.79e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—DBH—Parkinson's disease	1.13e-05	8.79e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—DRD2—Parkinson's disease	1.13e-05	8.78e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HTR7—Parkinson's disease	1.13e-05	8.78e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—INSR—Parkinson's disease	1.12e-05	8.73e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—DRD1—Parkinson's disease	1.12e-05	8.71e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TAC1—Parkinson's disease	1.12e-05	8.7e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CYP2D6—Parkinson's disease	1.12e-05	8.68e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ADRBK1—Parkinson's disease	1.12e-05	8.68e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CYP2E1—Parkinson's disease	1.11e-05	8.67e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—ABCB1—Parkinson's disease	1.1e-05	8.58e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—NQO1—Parkinson's disease	1.1e-05	8.57e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—DRD1—Parkinson's disease	1.1e-05	8.53e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CTGF—Parkinson's disease	1.1e-05	8.52e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—TH—Parkinson's disease	1.09e-05	8.45e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—DRD3—Parkinson's disease	1.08e-05	8.43e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HTR7—Parkinson's disease	1.08e-05	8.41e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—DRD2—Parkinson's disease	1.08e-05	8.41e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PLA2G6—Parkinson's disease	1.08e-05	8.39e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—GSTM1—Parkinson's disease	1.07e-05	8.33e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—MAOB—Parkinson's disease	1.07e-05	8.31e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—DRD3—Parkinson's disease	1.06e-05	8.26e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—FGB—Parkinson's disease	1.06e-05	8.25e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—HTR2A—Parkinson's disease	1.06e-05	8.23e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HTR1A—Parkinson's disease	1.06e-05	8.2e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CYCS—Parkinson's disease	1.04e-05	8.11e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TAC1—Parkinson's disease	1.04e-05	8.08e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—GPX1—Parkinson's disease	1.03e-05	7.97e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CYP2E1—Parkinson's disease	1.02e-05	7.94e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—DRD1—Parkinson's disease	1.02e-05	7.92e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ADRBK1—Parkinson's disease	1.01e-05	7.88e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—NQO1—Parkinson's disease	1.01e-05	7.85e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—TH—Parkinson's disease	9.95e-06	7.74e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ADRBK1—Parkinson's disease	9.92e-06	7.71e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—DRD3—Parkinson's disease	9.87e-06	7.67e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—HTR7—Parkinson's disease	9.81e-06	7.63e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—DRD2—Parkinson's disease	9.81e-06	7.63e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—DRD2—Parkinson's disease	9.61e-06	7.47e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HTR7—Parkinson's disease	9.61e-06	7.47e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CYCS—Parkinson's disease	9.56e-06	7.43e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IGF2—Parkinson's disease	9.52e-06	7.4e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IGF2—Parkinson's disease	9.47e-06	7.36e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—MTHFR—Parkinson's disease	9.46e-06	7.36e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—COMT—Parkinson's disease	9.24e-06	7.18e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ADRBK1—Parkinson's disease	9.22e-06	7.17e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IGF1R—Parkinson's disease	9.2e-06	7.15e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—GSTP1—Parkinson's disease	9.19e-06	7.15e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—MAOA—Parkinson's disease	9.17e-06	7.13e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IGF1R—Parkinson's disease	9.15e-06	7.12e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EDN1—Parkinson's disease	9.09e-06	7.07e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—HMOX1—Parkinson's disease	9.07e-06	7.05e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IGF2—Parkinson's disease	9.06e-06	7.05e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EDN1—Parkinson's disease	9.05e-06	7.03e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HTR7—Parkinson's disease	8.93e-06	6.94e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—DRD2—Parkinson's disease	8.93e-06	6.94e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—APOE—Parkinson's disease	8.81e-06	6.85e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IGF1R—Parkinson's disease	8.76e-06	6.81e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—ABCB1—Parkinson's disease	8.7e-06	6.77e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EDN1—Parkinson's disease	8.66e-06	6.73e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—COMT—Parkinson's disease	8.46e-06	6.58e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—GSTM1—Parkinson's disease	8.45e-06	6.57e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CYP2D6—Parkinson's disease	8.43e-06	6.55e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—GSTP1—Parkinson's disease	8.42e-06	6.55e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—MAOA—Parkinson's disease	8.4e-06	6.53e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NGF—Parkinson's disease	8.36e-06	6.5e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NGF—Parkinson's disease	8.31e-06	6.46e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—HMOX1—Parkinson's disease	8.31e-06	6.46e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—DDC—Parkinson's disease	8.3e-06	6.45e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CTGF—Parkinson's disease	8.27e-06	6.43e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IGF2—Parkinson's disease	8.22e-06	6.39e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—GPX1—Parkinson's disease	8.09e-06	6.29e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IGF2—Parkinson's disease	8.05e-06	6.26e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—ABCB1—Parkinson's disease	7.97e-06	6.2e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NGF—Parkinson's disease	7.96e-06	6.19e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—HTR2A—Parkinson's disease	7.95e-06	6.18e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IGF1R—Parkinson's disease	7.95e-06	6.18e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HTR2A—Parkinson's disease	7.91e-06	6.15e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EDN1—Parkinson's disease	7.85e-06	6.11e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTA4—Parkinson's disease	7.84e-06	6.09e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CTGF—Parkinson's disease	7.8e-06	6.06e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IGF1R—Parkinson's disease	7.78e-06	6.05e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—GSTM1—Parkinson's disease	7.74e-06	6.02e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CYP2E1—Parkinson's disease	7.71e-06	5.99e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EDN1—Parkinson's disease	7.69e-06	5.98e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—NQO1—Parkinson's disease	7.62e-06	5.93e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HTR2A—Parkinson's disease	7.57e-06	5.89e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—INS—Parkinson's disease	7.53e-06	5.85e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—TH—Parkinson's disease	7.51e-06	5.84e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IGF2—Parkinson's disease	7.48e-06	5.82e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—MTHFR—Parkinson's disease	7.47e-06	5.8e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—GPX1—Parkinson's disease	7.41e-06	5.76e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—APOE—Parkinson's disease	7.39e-06	5.75e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—APOE—Parkinson's disease	7.36e-06	5.72e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CYP2E1—Parkinson's disease	7.26e-06	5.65e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IGF1R—Parkinson's disease	7.23e-06	5.62e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NGF—Parkinson's disease	7.22e-06	5.61e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CYCS—Parkinson's disease	7.21e-06	5.61e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—NQO1—Parkinson's disease	7.18e-06	5.58e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EDN1—Parkinson's disease	7.15e-06	5.56e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—TH—Parkinson's disease	7.08e-06	5.5e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NGF—Parkinson's disease	7.07e-06	5.5e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	7.06e-06	5.49e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—APOE—Parkinson's disease	7.04e-06	5.48e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—MAOB—Parkinson's disease	6.99e-06	5.43e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—APOE—Parkinson's disease	6.95e-06	5.4e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—MTHFR—Parkinson's disease	6.84e-06	5.32e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CYCS—Parkinson's disease	6.8e-06	5.28e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HTR2A—Parkinson's disease	6.73e-06	5.23e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NGF—Parkinson's disease	6.57e-06	5.11e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—APOE—Parkinson's disease	6.39e-06	4.97e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—COMT—Parkinson's disease	6.39e-06	4.97e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—APOE—Parkinson's disease	6.37e-06	4.95e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GSTP1—Parkinson's disease	6.36e-06	4.94e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—MAOA—Parkinson's disease	6.34e-06	4.93e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—INS—Parkinson's disease	6.32e-06	4.91e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—INS—Parkinson's disease	6.28e-06	4.89e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—HMOX1—Parkinson's disease	6.27e-06	4.87e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—APOE—Parkinson's disease	6.26e-06	4.86e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HTR2A—Parkinson's disease	6.25e-06	4.86e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—COMT—Parkinson's disease	6.02e-06	4.68e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—INS—Parkinson's disease	6.02e-06	4.68e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSTP1—Parkinson's disease	5.99e-06	4.66e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—MAOA—Parkinson's disease	5.98e-06	4.65e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—INS—Parkinson's disease	5.94e-06	4.62e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—HMOX1—Parkinson's disease	5.91e-06	4.59e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GSTM1—Parkinson's disease	5.84e-06	4.54e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—APOE—Parkinson's disease	5.81e-06	4.52e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ABCB1—Parkinson's disease	5.67e-06	4.41e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GPX1—Parkinson's disease	5.59e-06	4.35e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSTM1—Parkinson's disease	5.5e-06	4.28e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—INS—Parkinson's disease	5.46e-06	4.24e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—INS—Parkinson's disease	5.44e-06	4.23e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—INS—Parkinson's disease	5.34e-06	4.15e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GPX1—Parkinson's disease	5.27e-06	4.1e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	5.19e-06	4.04e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—MTHFR—Parkinson's disease	5.16e-06	4.01e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CTGF—Parkinson's disease	5.1e-06	3.96e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—INS—Parkinson's disease	4.97e-06	3.86e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—MTHFR—Parkinson's disease	4.86e-06	3.78e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—APOE—Parkinson's disease	4.81e-06	3.74e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	4.75e-06	3.69e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CASP3—Parkinson's disease	4.7e-06	3.66e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NQO1—Parkinson's disease	4.7e-06	3.65e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CASP3—Parkinson's disease	4.68e-06	3.64e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL6—Parkinson's disease	4.67e-06	3.63e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL6—Parkinson's disease	4.65e-06	3.61e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—TH—Parkinson's disease	4.63e-06	3.6e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—APOE—Parkinson's disease	4.53e-06	3.52e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CASP3—Parkinson's disease	4.48e-06	3.48e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL6—Parkinson's disease	4.45e-06	3.46e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYCS—Parkinson's disease	4.44e-06	3.45e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MAPK8—Parkinson's disease	4.32e-06	3.36e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MAPK8—Parkinson's disease	4.3e-06	3.34e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MAPK8—Parkinson's disease	4.12e-06	3.2e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—INS—Parkinson's disease	4.11e-06	3.19e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CASP3—Parkinson's disease	4.06e-06	3.16e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL6—Parkinson's disease	4.04e-06	3.14e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CASP3—Parkinson's disease	3.98e-06	3.09e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL6—Parkinson's disease	3.95e-06	3.07e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—COMT—Parkinson's disease	3.94e-06	3.06e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTP1—Parkinson's disease	3.92e-06	3.04e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—MAOA—Parkinson's disease	3.91e-06	3.04e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—INS—Parkinson's disease	3.87e-06	3.01e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—HMOX1—Parkinson's disease	3.86e-06	3e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MAPK8—Parkinson's disease	3.73e-06	2.9e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ABCB1—Parkinson's disease	3.71e-06	2.88e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CASP3—Parkinson's disease	3.7e-06	2.87e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL6—Parkinson's disease	3.67e-06	2.86e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MAPK8—Parkinson's disease	3.66e-06	2.84e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTM1—Parkinson's disease	3.6e-06	2.8e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GPX1—Parkinson's disease	3.45e-06	2.68e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAPK8—Parkinson's disease	3.4e-06	2.64e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—MTHFR—Parkinson's disease	3.18e-06	2.47e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—APOE—Parkinson's disease	2.96e-06	2.3e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL6—Parkinson's disease	2.76e-06	2.15e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL6—Parkinson's disease	2.75e-06	2.14e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL6—Parkinson's disease	2.63e-06	2.04e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—INS—Parkinson's disease	2.53e-06	1.97e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL6—Parkinson's disease	2.38e-06	1.85e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL6—Parkinson's disease	2.33e-06	1.82e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6—Parkinson's disease	2.17e-06	1.69e-05	CbGpPWpGaD
